Patients with corrected Hypoglycemia taking sulfonylureas (glyburide, glipizide, etc) are at risk for what?

Patients with corrected Hypoglycemia taking sulfonylureas (glyburide, glipizide, etc) are at risk for what?

• A. Hyperglycemia
• B. Seizures
• C. Repeat episodes of hypoglycemia and hospitalization
• D. Hypertension

Answer: (C)

The key idea is that sulfonylureas keep driving insulin release from the pancreas, so even after you’ve corrected the initial low blood sugar, the drug’s effect can persist and cause another hypoglycemic episode. This makes repeat hypoglycemia a real risk that can lead to hospitalization for monitoring and treatment. The problem isn’t just a one-time event—the medication can cause ongoing lows for hours, particularly in older patients or those with kidney or liver impairment, so careful follow-up and possible medication adjustments are important. Seizures can happen with severe hypoglycemia, but the scenario specifically highlights the recurrent lows due to the continued action of the drug, not hypertension or hyperglycemia.

The key idea is that sulfonylureas keep driving insulin release from the pancreas, so even after you’ve corrected the initial low blood sugar, the drug’s effect can persist and cause another hypoglycemic episode. This makes repeat hypoglycemia a real risk that can lead to hospitalization for monitoring and treatment. The problem isn’t just a one-time event—the medication can cause ongoing lows for hours, particularly in older patients or those with kidney or liver impairment, so careful follow-up and possible medication adjustments are important. Seizures can happen with severe hypoglycemia, but the scenario specifically highlights the recurrent lows due to the continued action of the drug, not hypertension or hyperglycemia.